BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orphan designation in treatment of Waldenstrom macroglobulinemia, according to a post on the agency’s site.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: